Close Menu

High Intensity Focused Ultrasound Therapy Combined Gemcitabine for Treating Unresectable Pancreatic Carcinoma

DOI: 
10.7727/wimj.2016.013

ABSTRACT

Objective: To study therapeutic effect and safety of high intensity focused ultrasound (HIFU) combined Gemcitabine on unresectable pancreatic carcinoma (PC).

Methods: Total 45 PC patients were randomly divided into 2 groups: experimental group (treating with HIFUT and gemcitabine, n=23), control group (treating with gemcitabine only, n=22). The therapeutic effects and clinical benefit rates in two groups were compared by using the Kaplan-Meier and Log-Rank tests, including the median survival time (MST), 6-month and 12-month survival rates.

Results: Our results showed thatMST and 6-month survival rates of experimental patients were significantly higher than that of control patients (8.91 vs 5.53 mths, 73.9 vs 40.9%, p<0.05). For the 12-month survival rates, no statistically difference was observed between the two groups (13.0 vs 4.5%, p>0.05). The clinical benefit rates in experimental group and control group were 69.6% and 36.3%, respectively (p<0.05). The pain remission rate in experimental group was significantly higher than in control group (65.2 vs. 31.8%, p<0.05).

Conclusions: For treating pancreatic carcinoma, HIFUT combined gemcitabine is better than gemcitabine only. The former treatment (HIFUT combined gemcitabine) may become a better effective treatment strategy for treating unresectable pancreatic carcinoma.

Accepted: 
21 Jan, 2016
PDF Attachment: 
e-Published: 23 Feb, 2016

Disclaimer

Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.

Top of Page